AstraZeneca : COVID-19 vaccine: good data but not the best
>AstraZeneca is satisfied with its preliminary vaccine efficacy - AZN published the interim analysis for the phase III trial of its COVID-19 vaccine just before trading yesterday. In close to 12,000 volunteers, of whom 131 contracted the disease 14 days after the second injection, AZD1222 saw an average reduction of 70% in the risk of developing the symptomatic disease relative to the placebo. But this efficacy differed depending on the vaccine dose. Vaccine efficacy ...AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.